GINA 2020: Opportunities and challenges for primary care

In 2019, it was reported that changes to asthma management reported in the Global Initiative for Asthma “….might be considered the most fundamental changes in asthma management in 30 years.”. These changes refer to the recommendation that the treatment of asthma in adolescents and adults would no longer include short acting ß₂ agonist (SABA) only, but that people with asthma should receive either symptom-driven inhaled corticosteroids (ICS)-containing treatment (mild asthma) or daily ICS-containing treatment. The fundamental reason for this shift was driven by concerns about the risks and consequences associated with SABA only treatment, the need to improve the day-to-day management of asthma symptoms to prevent exacerbations and emergent evidence. These recommendations have subsequently been reinforced and characterized in GINA 2020  and it is reasonable to say that they are significant: not only in terms of an asthma management framework, but also as a management approach in practice. This opinion article specifically focuses on opportunities and challenges associated with the implementation of GINA 2020 in primary care practice which need to be recognised and addressed if the shift in asthma treatment paradigm is to be successfully implemented into day-to-day practice.